MiNK Therapeutics, Inc. INKT

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
55/100
Moderate

Ranked against 712 peers in Biotechnology

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the … Full INKT analysis →

Key strengths

  • ROIC Sustainably Above Peers ROIC at 93.3th percentile exceeds peers and WACC, demonstrating superior capital allocation.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.30), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.12), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where INKT ranks in Biotechnology

MiNK Therapeutics, Inc. ranks #174 of 713 scored companies in Biotechnology by moat score — the top 24%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
170 Geron Corporation GERN 55/100 Moderate
171 Oric Pharmaceuticals, Inc. ORIC 55/100 Moderate
172 Repare Therapeutics Inc. RPTX 55/100 Moderate
173 Madrigal Pharmaceuticals, Inc. MDGL 55/100 Moderate
174 MiNK Therapeutics, Inc. INKT 55/100 Moderate
175 Arcutis Biotherapeutics, Inc. ARQT 55/100 Moderate
176 Immunic, Inc. IMUX 55/100 Moderate
177 Ocean Biomedical, Inc. OCEA 55/100 Moderate
178 OmniAb, Inc. OABI 55/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How INKT scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 75 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 24 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding INKT's moat

What is MiNK Therapeutics, Inc.'s moat score?

MiNK Therapeutics, Inc. (INKT) scores 55 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #174 of 713 scored companies in Biotechnology, the top 24%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (75/100) and its weakest is Resilience (24/100).

How does MiNK Therapeutics, Inc. compare with other Biotechnology companies?

MiNK Therapeutics, Inc. ranks #174 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Madrigal Pharmaceuticals, Inc. (MDGL) at 55 just above it and Arcutis Biotherapeutics, Inc. (ARQT) at 55 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is MiNK Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for MiNK Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and INKT scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (75), Resilience (24), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000